Liquidia Corporation (LQDA) financial statements and ratios from SEC XBRL: revenue $0.5B (TTM), net margin -43.5%, revenue growth 1842.7% YoY, P/E 43.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $158.32M |
| Revenue (TTM) | $0.5B |
| Net Margin | -43.5% |
| Return on Equity | 71.0% |
| Operating Margin (TTM) | 37.4% |
| Current Ratio | 2.31 |
| Net Debt / EBITDA | -1.7 |
| Interest Coverage | 6.3 |
| Revenue Growth (YoY) | 1842.7% |
| EPS Growth (YoY) | -271.4% |
| FCF Growth (YoY) | -270.2% |
| P/E Ratio | 43.1 |
| EV / EBITDA | 33.5 |
| Price / Book | 30.62 |
| Price / Sales | 13.25 |
| FCF Yield | 1.1% |
| Altman Z-Score | 10.26 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
LQDA overview · LQDA earnings · LQDA KPIs · LQDA documents · LQDA ownership · LQDA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.